Neurotech International Ltd. (AU:NTI)
ASX:NTI
Top Page
Neurotech International
(Sydney:NTI)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.01
▼(-50.00% Downside)
Action:ReiteratedDate:02/19/26
The score is driven primarily by weak financial performance: persistent heavy losses, accelerating cash burn, and a reduced equity base despite zero debt and a revenue rebound. Technicals also lean negative (below key moving averages and negative MACD), while valuation is constrained by a negative P/E and no dividend support.
Positive Factors
Zero debt / low leverage
Zero reported debt materially lowers solvency and interest-service risk, giving management flexibility to prioritize R&D and clinical programs. For a cash-burning biotech, a debt-free structure reduces near-term liquidity stress and preserves optionality to raise equity or non-debt financing more conservatively.
Negative Factors
Consistent negative operating and free cash flow
Persistent and worsening negative free cash flow indicates the business is not self-funding; accelerating cash burn as activity ramps raises near-term financing needs. This structural cash deficit increases dilution and funding risk and constrains long-term program execution if external capital is limited.
Read all positive and negative factors
Positive Factors
Negative Factors
Zero debt / low leverage
Zero reported debt materially lowers solvency and interest-service risk, giving management flexibility to prioritize R&D and clinical programs. For a cash-burning biotech, a debt-free structure reduces near-term liquidity stress and preserves optionality to raise equity or non-debt financing more conservatively.
Read all positive factors
Neurotech International (NTI) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$16.85M
Dividend YieldN/A
Average Volume (3M)768.84K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth-87.88%
EPS Growth-83.93%
CountryAU
Employees18
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,296,313,100
10 Day Avg. Volume770,041
30 Day Avg. Volume768,844
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)5.26
Price to Sales (P/S)6.36
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Neurotech International Business Overview & Revenue Model
Company Description
Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform,...
How the Company Makes Money
NTI’s revenue model is not clearly disclosed in the provided context and cannot be stated with specificity. null...
Neurotech International Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.33M | 2.44M | 1.96K | 5.96K | 38.26K | 206.14K |
| Gross Profit | 8.02M | 2.44M | -5.87K | 4.21K | -535.21K | -238.72K |
| EBITDA | -8.72M | -10.74M | -8.24M | -8.98M | -3.36M | -7.43M |
| Net Income | -3.85M | -10.60M | -5.07M | -7.79M | -3.36M | -7.43M |
Balance Sheet | ||||||
| Total Assets | 6.81M | 3.24M | 12.21M | 5.31M | 2.02M | 5.01M |
| Cash, Cash Equivalents and Short-Term Investments | 6.34M | 3.03M | 11.63M | 5.03M | 1.90M | 4.83M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 932.85K | 285.74K | 314.70K | 1.35M | 592.98K | 1.14M |
| Stockholders Equity | 5.88M | 2.95M | 11.90M | 3.96M | 1.43M | 3.86M |
Cash Flow | ||||||
| Free Cash Flow | -2.97M | -9.02M | -4.60M | -6.32M | -2.96M | -2.32M |
| Operating Cash Flow | -2.97M | -9.02M | -4.60M | -6.32M | -2.96M | -2.32M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -3.21K | 0.00 |
| Financing Cash Flow | 3.35M | 429.53K | 11.19M | 9.45M | 26.40K | 7.13M |
Neurotech International Technical Analysis
Negative
0.02
Price Trends
0.01
Negative
0.01
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
45.63
Neutral
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NTI, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.01, above the 50-day MA of 0.01, and above the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.63 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NTI.
Neurotech International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$23.07M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
47 Neutral | AU$32.41M | -4.09 | -58.40% | ― | -7.20% | 28.70% | |
43 Neutral | AU$16.85M | -5.30 | -87.19% | ― | -87.88% | -83.93% | |
41 Neutral | AU$10.75M | -0.50 | 459.94% | ― | -2.82% | 32.47% | |
39 Underperform | AU$15.81M | -1.00 | -372.27% | ― | 126.62% | 33.53% |
* Healthcare Sector Average
AU:NTI
Neurotech International
0.01
-0.02
-60.61%
AU:AT1
Atomo Diagnostics Ltd.
0.04
0.02
100.00%
AU:ADR
Adherium Ltd.
0.01
0.00
0.00%
AU:CBL
Control Bionics Ltd.
0.06
0.01
27.27%
AU:OSL
OncoSil Medical Ltd
0.52
-0.43
-45.44%
Neurotech International Corporate Events
Neurotech to Highlight Paediatric Neurology Pipeline at NWR Virtual Healthcare Conference
Mar 22, 2026
Neurotech International, a clinical-stage biopharmaceutical company specialising in paediatric neurological disorders, is advancing NTI164, a proprietary CBDA-rich cannabinoid formulation targeting neuroinflammatory and immune pathways in conditio...
Neurotech Flags Risks and Uncertainties in Neurodevelopmental Drug Strategy
Mar 17, 2026
Neurotech International has outlined its current corporate strategy and development plans for treatments targeting neurodevelopmental disorders, under the leadership of CEO and Managing Director Dr Anthony Filippis. The company highlights that its...
Neurotech Investors Back Capital Raisings and Director Participation at General Meeting
Mar 12, 2026
Neurotech International has reported the results of its 12 March general meeting in Melbourne, where all resolutions were decided by poll, including the ratification of previously issued placement shares and approvals for additional equity issuanc...
Neurotech Narrows Half-Year Loss as Revenue Doubles
Feb 26, 2026
Neurotech International reported a 100% increase in revenue from ordinary activities to $4.7 million for the half year to 31 December 2025, while its net loss attributable to owners narrowed sharply to $697,000, down 91% from the prior correspondi...
Neurotech’s NTI164 Shows Strong Long-Term Safety in Key Toxicology Study
Feb 22, 2026
Neurotech International has reported that its lead oral cannabinoid candidate NTI164 demonstrated a favourable long-term safety and tolerability profile in a 90-day GLP repeat-dose toxicity study in Beagle dogs, with no mortality, dose-limiting to...
Neurotech International Calls March General Meeting, Moves to Digital Meeting Notices
Feb 10, 2026
Neurotech International has called a general meeting of shareholders to be held as a physical gathering at BDO Australia’s Melbourne offices on 12 March 2026 at 11:00 a.m. AEDT. In line with recent Corporations Act changes, the company will ...
Neurotech Wins Ethics Approval for Pivotal Phase 3 Autism Trial of NTI164
Feb 2, 2026
Neurotech International has secured Human Research Ethics Committee approval to begin its Beyond Harmony Phase 3 clinical study of NTI164 in individuals with autism spectrum disorder Levels 2 and 3, a pivotal step in its strategy to commercialise ...
Neurotech Advances Lead Paediatric Neurology Drug NTI164 with New FDA Designation, Data and Funding
Jan 30, 2026
Neurotech International reported a pivotal quarter marked by the US FDA granting Rare Pediatric Disease Designation to its lead drug NTI164 for Rett syndrome, adding to existing US and European Orphan Drug Designations and significantly enhancing ...
Neurotech’s NTI164 PANS Data Published in Leading Journal, Bolstering Paediatric Neuro Portfolio
Jan 14, 2026
Neurotech International has reported that clinical and mechanistic data for its proprietary medicinal cannabis‑derived drug NTI164 in paediatric acute‑onset neuropsychiatric syndrome (PANS) have been published in Neurotherapeutics, a h...
Neurotech Issues New Shares, Affirms Regulatory Compliance
Dec 24, 2025
Neurotech International has issued new ordinary fully paid shares without a prospectus under the Corporations Act, confirming that it remains compliant with its financial reporting and continuous disclosure obligations and that there is no exclude...
Neurotech Seeks ASX Quotation for 246.7 Million New Shares
Dec 24, 2025
Neurotech International has applied to the ASX for quotation of 246.7 million new ordinary fully paid shares, expanding its listed securities on the Australian market. The issuance, lodged via an Appendix 2A application and tied to previously flag...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.